Login to Your Account



Basilea Shares Rise on $89M BARDA Contract for BAL30072

By Cormac Sheridan
Staff Writer

Tuesday, June 25, 2013
Shares in Basilea Pharmaceutica AG gained as much as 6 percent during mid-morning trading Tuesday on news that it secured a contract from the U.S. Biomedical Advanced Research and Development Authority (BARDA), worth up to $89 million, for the development of its antibiotic, BAL30072.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription